Specific Features of the Course of Acute Coronary Syndrome in Patients with Newly Developed Atrial Fibrillation in Clinical Practice According to the Data of the Register of Acute Coronary Syndrome

Aim: to elucidate risk factors of development of atrial fibrillation (AF) in patients with acute coronary syndrome (ACS), and to assess of patient’s adherence to oral anticoagulant therapy (OAT) during 12 months after ACS episode according to the data of the Total ACS Registry for the Krasnodar Territory.

Materials and methods. In this retrospective analysis we used Registry data on patients with ACS and concomitant AF, consecutively admitted to cardiological departments of the S.V. Ochapovsky Territorial Clinical Hospital from 20/11/2015 to 20/02/18. Number of patients in the analyzed group was 201 (52 with AF which first appeared in connection with the index ACS). Survivors after hospital discharge were contacted by telephone and at planned visits. The analysis included assessment of rates of the following outcomes: inhospital death, hemorrhagic and thromboembolic complications, prognostic efficacy of the CRISADE and HAS BLED scores, and expediency of prescription to patients with ACS and concomitant first AF episode of prolonged OAT after hospital discharge.

Results. Demographic and anamnestic data of patients with the first AF attack at the background of ACS were like those of patients with other types of AF. This group of patients was characterized by more severe course of the disease, but this produced no impact on inhospital mortality and rate of complications, as well as on mortality for 12 months after hospital discharge.

Conclusion. The results of this analysis are important for understanding distinctive characteristics of patients with AF first developed during ACS.

1. Montalescot G, Sechtem W, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. DOI: 10.1093/eurheartj/eht296

2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609– 78. DOI: 10.1093/europace/euw295

3. Burokienė N, Domarkienė I, Ambrozaitytė L, Uktverytė I, Meškienė R, Karčiauskaitė D et al. Classical rather than genetic risk factors account for high cardiovascular disease prevalence in Lithuania: A cross-sectional population study. Advances in Medical Sciences. 2017;62(1):121–8. DOI: 10.1016/j.advms.2016.08.005

4. Christodoulidis G, Vittorio TJ, Fudim M, Lerakis S, Kosmas CE. Inflammation in Coronary Artery Disease: Cardiology in Review. 2014;22(6):279–88. DOI: 10.1097/CRD.0000000000000006

5. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine. 2009;360(7):668–78. DOI: 10.1056/NEJMoa0803778

6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561

8. Smit MD, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M, Tuininga YS et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. Journal of the American College of Cardiology. 2011;58(9):942–9. DOI: 10.1016/j.jacc.2011.04.030

9. Otterstad JE, Kirwan B-A, Lubsen J, De Brouwer S, Fox KAA, Corell P et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. Scandinavian Cardiovascular Journal. 2006;40(3):152–9. DOI: 10.1080/14017430600746268

10. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA et al. Atrial Fibrillation and Death After Myocardial Infarction: A Community Study. Circulation. 2011;123(19):2094–100. DOI: 10.1161/CIRCULATIONAHA.110.990192

11. Alasady M, Abhayaratna WP, Leong DP, Lim HS, Abed HS, Brooks AG et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8(7):955–60. DOI: 10.1016/j.hrthm.2011.02.016

12. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101(9):969–74. PMID: 10704162

13. Stenestrand U. Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences LongTerm Outcome: A Prospective Cohort Study From the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005;112(21):3225– 31. DOI: 10.1161/CIRCULATIONAHA.105.552984

14. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008;94(7):867–73. DOI: 10.1136/hrt.2007.134486

15. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F et al. Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis. Circulation. 2011;123(15):1587–93. DOI: 10.1161/CIRCULATIONAHA.110.986661

16. Berton G, Cordiano R, Cucchini F, Cavuto F, Pellegrinet M, Palatini P. Atrial fibrillation during acute myocardial infarction: association with all-cause mortality and sudden death after 7-year of follow-up. International Journal of Clinical Practice. 2009;63(5):712–21. DOI: 10.1111/j.1742-1241.2009.02023.x

17. Kundu A, O’Day K, Shaikh AY, Lessard DM, Saczynski JS, Yarzebski J et al. Relation of Atrial Fibrillation in Acute Myocardial Infarction to In-Hospital Complications and Early Hospital Readmission. The American Journal of Cardiology. 2016;117(8):1213–8. DOI: 10.1016/j.amjcard.2016.01.012

18. Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, KlineRogers EM, Anderson FA et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. The American Journal of Cardiology. 2003;92(9):1031–6. DOI: 10.1016/j.amjcard.2003.06.001

19. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. European Heart Journal. 2005;26(4):350–6. DOI: 10.1093/eurheartj/ehi064

20. Aronson D, Mutlak D, Bahouth F, Bishara R, Hammerman H, Lessick J et al. Restrictive Left Ventricular Filling Pattern and Risk of New-Onset Atrial Fibrillation After Acute Myocardial Infarction. The American Journal of Cardiology. 2011;107(12):1738–43. DOI: 10.1016/j.amjcard.2011.02.334

21. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. European Heart Journal. 2009;30(9):1038–45. DOI: 10.1093/eurheartj/ehn579

22. Ogawa H, An Y, Ikeda S, Aono Y, Dоі K, Ishii M et al. Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. Stroke. 2018;49(10):2301–8. DOI: 10.1161/STROKEAHA.118.021396

23. Senoo K, Lip GYH, Lane DA, Büller HR, Kotecha D. Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. Stroke. 2015;46(9):2523–8. DOI: 10.1161/STROKEAHA.115.009487

24. Steensig K, Olesen K, Thim T, Nielsen J, Jensen S, Jensen L et al. Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. Thrombosis and Haemostasis. 2018;118(12):2162–70. DOI: 10.1055/s-0038-1675401

25. Ruigómez A, Johansson S, Wallander M-A, Edvardsson N, García Rodríguez LA. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. International Journal of Cardiology. 2009;136(2):186–92. DOI: 10.1016/j.ijcard.2008.04.050

26. Jons C, Jacobsen UG, Joergensen RM, Olsen NT, Dixen U, Johannessen A et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: A CARISMA substudy. Heart Rhythm. 2011;8(3):342–8. DOI: 10.1016/j.hrthm.2010.09.090

27. Kinjo K, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. The American Journal of Cardiology. 2003;92(10):1150–4. PMID: 14609587